about
Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillationA KCNQ1 mutation contributes to the concealed type 1 long QT phenotype by limiting the Kv7.1 channel conformational changes associated with protein kinase A phosphorylationGain-of-function mutation of Nav1.5 in atrial fibrillation enhances cellular excitability and lowers the threshold for action potential firingUse of implantable cardioverter defibrillators in Canadian and US survivors of out-of-hospital cardiac arrestGenetics of inherited primary arrhythmia disordersA mutation in the atrial-specific myosin light chain gene (MYL4) causes familial atrial fibrillation.PRKAG2 cardiac syndrome: familial ventricular preexcitation, conduction system disease, and cardiac hypertrophyTargeted deep sequencing reveals no definitive evidence for somatic mosaicism in atrial fibrillation.The short QT syndrome: proposed diagnostic criteria.Sentinel symptoms in patients with unexplained cardiac arrest: from the cardiac arrest survivors with preserved ejection fraction registry (CASPER).A KCNQ1 mutation causes a high penetrance for familial atrial fibrillation.Evolution of clinical diagnosis in patients presenting with unexplained cardiac arrest or syncope due to polymorphic ventricular tachycardia.Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients.Frequency of peripartum cardiomyopathy.Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome.Evaluation of non-synonymous NPPA single nucleotide polymorphisms in atrial fibrillationRecommendations for the use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position paper.Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation.Meta-analysis identifies six new susceptibility loci for atrial fibrillationCardiac connexins as candidate genes for idiopathic atrial fibrillation.Clinical trials, the renin angiotensin system and atrial fibrillation.Chronic AMPK activity dysregulation produces myocardial insulin resistance in the human Arg302Gln-PRKAG2 glycogen storage disease mouse model.Begetting atrial fibrillation: Connexins and arrhythmogenesis.The genetic and clinical features of cardiac channelopathies.HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA).HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA).The role of atrial natriuretic peptide in modulating cardiac electrophysiology.The genetics of cardiac disease associated with sudden cardiac death: a paper from the 2011 William Beaumont Hospital Symposium on molecular pathology.Voltage-gated sodium channels: biophysics, pharmacology, and related channelopathies.Genetics of cardiac electrical disease.A practical guide to early repolarization.Go protein subunit Goα and the secretory process of the natriuretic peptide hormones ANF and BNP.Outcome of Apparently Unexplained Cardiac Arrest: Results From Investigation and Follow-Up of the Prospective Cardiac Arrest Survivors With Preserved Ejection Fraction Registry.Epinephrine infusion in the evaluation of unexplained cardiac arrest and familial sudden death: from the cardiac arrest survivors with preserved Ejection Fraction Registry.Loss-of-Function KCNE2 Variants: True Monogenic Culprits of Long-QT Syndrome or Proarrhythmic Variants Requiring Secondary Provocation?Prevalence and Clinical Implication of Double Mutations in Hypertrophic Cardiomyopathy: Revisiting the Gene-Dose Effect.Rapid Device-Detected Nonsustained Ventricular Tachycardia in the Risk Stratification of Hypertrophic Cardiomyopathy.Evaluation of Prolonged QT Interval: Structural Heart Disease Mimicking Long QT Syndrome.Predictors of fracture risk of a small caliber implantable cardioverter defibrillator lead.Patient Outcomes From a Specialized Inherited Arrhythmia Clinic.
P50
Q24294428-F27BBF1C-D198-426B-A045-2024E74B4DC1Q24309447-6840A7AB-2453-4C93-B8EC-E6EFB888C119Q24321619-6DC530B9-BECF-47D9-B4BD-1BC6F9940BFDQ24685115-025BEF61-8955-40D7-9680-A667C6FCA145Q26783570-4D41172B-714A-401B-828D-4674F2256A52Q27319899-2D3DEAED-16DC-4358-A230-0CAB22101ECEQ28217924-77170986-3F80-43AF-9E52-071BD8B37448Q30392171-F968D7A7-F2AA-4564-B207-302874C2D081Q33159709-06A8D5F5-0B63-4CDF-B951-D73ACD878AD0Q33160503-E2E6EAC3-D983-4F6F-B7EA-B79F2E4643DEQ33162279-1E522739-4CED-4F0F-A573-74C06F5117E0Q33163530-6050D6BF-0E6B-450D-ADA5-04B9868D5992Q33168674-4E141AB2-E60F-4AB8-A6F9-F85D7F27E07EQ33996675-E8361C5B-AE92-48AC-88A6-CCDC10C23DCEQ34012881-F3EF79F1-8848-4C89-A18C-8874C88C4F2FQ34022405-F4B68F06-EDDF-4D9E-82FF-7EF41C2ED049Q34175202-A1EE585E-A2E7-4B2A-93E2-E91938DDB420Q34307746-B0BEDBB3-60CC-4D78-A127-31FCF6CD37ADQ36004061-AF5D2CAD-8D84-47DC-BF66-AB074D4EB9DFQ36443117-12AB7FF2-7EC9-427D-AF25-0ABC200140AFQ36497948-91F62B1B-FA71-46FC-B033-83C705A7D34DQ37000786-7D222139-A758-441D-AB42-43933764AB22Q37183628-BE2EFAD5-BFCD-4073-A404-64D3129D8455Q37770572-136D5BA1-27BE-4581-9154-CC8182A58E61Q37905310-FF8254AE-802C-4D76-A23B-F1A23614048DQ37910512-E9C7CBF8-9F59-496E-935C-29E606D86304Q37956108-D071BA0F-13D2-40F4-9A22-52C95ED0EB81Q38023030-4EFC3DAA-F1A2-4679-B33A-BFB87028511BQ38026557-EDDF7128-D5BB-40B2-9638-9034D88EDE86Q38051821-FAECCE43-173A-4F23-8FA6-B9A62B76CA33Q38267411-F80D0626-765D-4407-8652-590A4A896150Q38299440-0F8F69D8-059F-493F-A302-A0BEAE066347Q38397020-AA28F0F6-612C-4F1E-849C-322E82EF059DQ38464723-E7B56796-CDF0-49E0-8AAE-7507AF9BE8FDQ38631722-CEEFE35A-EC8D-49AA-ACC0-A62BEB0679BEQ38831514-4E510104-E6E3-4680-BB1B-92EC198FD4E0Q38888427-9A446161-BC89-431B-8B35-7E89E3ADB00FQ39117176-2E188D8F-9D42-4813-8976-9228E87658CFQ39923665-63EC4C5B-8AA9-476B-8F52-F2006D2BC697Q40131213-22B09360-4E37-400C-A87E-AEE8639C1A17
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michael H Gollob
@es
Michael H Gollob
@nl
Michael H Gollob
@sl
Michael H. Gollob
@en
type
label
Michael H Gollob
@es
Michael H Gollob
@nl
Michael H Gollob
@sl
Michael H. Gollob
@en
prefLabel
Michael H Gollob
@es
Michael H Gollob
@nl
Michael H Gollob
@sl
Michael H. Gollob
@en
P106
P1153
6602231138
P21
P31
P496
0000-0003-0242-5208